Beijing, China, May 12 — Gan & Lee Pharmaceuticals (hereinafter referred to as Gan & Lee, stock code: 603087.SH) has achieved a major milestone in its development. Brazil's Minister of Health, Alexandre Padilha, along with Biomm CEO Heraldo Marchezini and representatives from the Brazilian Embassy in China, visited the headquarters of Gan & Lee and signed a cooperation agreement under Brazil's Productive Development Partnership (Parcerias para o Desenvolvimento Produtivo, PDP) project—a key project of Brazil's national public health system. This milestone establishes Gan & Lee as the first Chinese pharmaceutical company to participate in Brazil's PDP project, marking a new phase of technological collaboration and industrial synergy between China and Brazil in the biopharmaceutical sector. The partnership will significantly advance Brazil's efforts in localizing insulin production while contributing to global diabetes prevention and treatment.

The PDP project is a critical component of Brazil's public health system reform, designed to strengthen healthcare infrastructure and ensure stable supplies of essential medicines. This agreement was formalized during Brazilian President Luiz Inácio Lula da Silva's state visit to China, following both the February 2025 approval of Gan & Lee' insulin PDP project and subsequent April discussions with Brazil's Ministry of Health - meetings conducted at Biomm's invitation. These developments collectively represent a significant strategic milestone for the initiative.

Biomm's strategic collaboration with Gan & Lee, established in 2014, has yielded significant achievements - most notably the successful registration and commercialization of insulin glargine in the Brazilian market. This partnership has provided Gan & Lee with critical internationalization experience that continues to inform its global expansion strategy.

While strengthening its international partnerships, Gan & Lee has maintained an unwavering commitment to innovation-led growth, consistently boosting R&D expenditures and building a diversified portfolio of innovative drug candidates. The newly signed PDP initiative with Brazil's Ministry of Health represents the perfect convergence of the company's formidable R&D capabilities and global strategic vision. This collaboration not only bridges a critical gap in Sino-Brazilian biopharmaceutical cooperation but also establishes a benchmark for Chinese pharmaceutical enterprises' engagement in global public health governance.

Du Kai stated, “Through this collaboration, we are putting into practice the Belt and Road Initiative of joint consultation, collective contribution and shared benefits. Not only does this strengthen the resilience of Brazil's pharmaceutical supply chain, but it also delivers a distinctive Chinese approach to establishing reliable insulin access across South America. Alexandre Padilha, Brazil's Minister of Health, emphasized the national strategic importance of this collaboration. At the signing ceremony, he stated: "The PDP project will not only guarantee medication accessibility for Brazilian diabetes patients, but will also systematically upgrade Brazil's biopharmaceutical capabilities, establishing the foundation for domestic insulin production. We consider this cooperation as a crucial starting point for deepening strategic relations between Brazil and Gan & Lee, with expectations to expand into broader healthcare area in the future. This partnership actively responds to the policy initiatives of China and Brazil regarding the joint construction of building a community with a shared future for mankind, collaborating to tackle health challenges and promote the advancement of healthcare."

Following the signing ceremony, the Brazilian delegation toured Gan & Lee's R&D Center and manufacturing facilities for a first-hand assessment of the company's operations. The delegation commended Gan & Lee's remarkable achievements in insulin analog research and industrial production, recognizing these capabilities as crucial for ensuring the successful execution of the upcoming PDP project.

This collaboration marks a leapfrog development in the biopharmaceutical field between China and Brazil, transitioning from technology sharing to industrial synergy. The project, centered on the localized production of insulin, aims to help Brazil break through technological barriers in the biopharmaceutical sector, achieve domestic production of insulin preparations, and strengthen the stable supply of insulin. As the first Chinese pharmaceutical company to participate in Brazil's PDP project, Gan & Lee has leveraged innovative technologies to break multinational pharmaceutical monopolies while ensuring stable drug supply. This achievement demonstrates Chinese pharma's commitment to global health governance, establishing a pioneering model for technology equity and livelihood improvement under the Belt and Road Initiative.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.